CRBN and Miyoshi myopathy: In contrast, the treatment of MM cells, regardless of their steady-state levels of CRBN, with AGO2-shRNA-74 significantly induced apoptosis (Fig. 8c), suggesting that AGO2 could be considered as a novel drug target to overcome IMiD resistance.